rCD4s from HIV-1⁺ Pts are coated with gp120.

<p>(<b>a</b>) Representative FACS data from rCD4s purified from healthy controls (H1, H2) or chronic asymptomatic patients (Pt-f2r1, Pt-f2r2) stained with Leu3a and CD4v4 (numbers in FACS plots indicate percentages of MFIs of Leu3a/CD4v4). (<b>b</b>) Summary of results of percentages of MFIs of Leu3a/CD4v4 in purified rCD4s from healthy controls (H) and chronic asymptomatic patients (C; CD4 counts: 420±84.6 (± SD); IgG⁺ rCD4s: 75.5±12.6% (± SD)). (<b>c, d</b>) Detection of cell-bound gp120 on rCD4s in a patient with low anti-gp120 Ab levels. (<b>c</b>) Western blot test results for the HIV-1⁺ Pt (NDA-01) at initial admission and three months after. N, negative control; Pt, patient serum; Po, positive control. HIV-1 infection was defined as detectable amounts of plasma HIV-1 RNA (1.5×10⁵ copies/ml at initial admission), a positive antibody test (HIV1/2 ELISA), and low CD4⁺ T cell counts (38 cells/µl). Plasma HIV-1 env and gag region sequences revealed that the patient was infected with a clade B HIV-1. (<b>d</b>) FACS data from rCD4s stained with anti-IgG (upper left), anti-IgM (upper right), anti-gp120 (rabbit anti-gp120 antiserum) (lower left), or purified IgG from pooled serum from HIV-1⁺ Pts (lower right).